Omnicell buys med management developer for $156M
Supply management tools and analytics software developer Omnicell has completed the acquisition of MTS Medication Technologies, a medication management equipment and software developer, for $156 million.
The combination of Omnicell and MTS is expected to establish a company that can integrate medication management across care delivery. MTS will continue to operate under its current brand, as a wholly owned subsidiary of Omnicell, immediately following the closing of the acquisition, according to Mountain View, Calif.-based Omnicell. MTS reportedly serves 6,000 pharmacies globally.
The combination of Omnicell and MTS is expected to establish a company that can integrate medication management across care delivery. MTS will continue to operate under its current brand, as a wholly owned subsidiary of Omnicell, immediately following the closing of the acquisition, according to Mountain View, Calif.-based Omnicell. MTS reportedly serves 6,000 pharmacies globally.